Resolve Scores The Option Of An Exit With Takeda Tie-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Resolve Therapeutics and Takeda Pharmaceuticals have agreed to an option agreement that will add to the Japanese pharma’s immunology pipeline while also providing a path to an eventual exit for the biotech’s investors.